Business Wire

TX-ROKA

Share
Javier Gómez Noya Chooses ROKA Eyewear

ROKA , the Austin-based performance design company, has announced a multiyear eyewear partnership with eight-time triathlon world champion and Olympic silver medalist Javier Gómez Noya , expanding their existing relationship for technical race apparel and equipment. Starting in 2018, Gómez will train and race in ROKA’s eyewear, the lightest, most advanced performance optics in the world, in the pursuit of his first Ironman World Championship.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426006510/en/

“I first tried the Advanced Performance eyewear while I was at ROKA’s headquarters in Texas, and right away I knew they were the glasses I should be using everyday,” Gómez Noya says. “There’s nothing like them in terms of weight, retention, and quality of vision. Whether cycling or running, you can’t feel that you’re wearing them but you have an incredible field of view.”

Gómez Noya began his partnership with ROKA four years ago, when he chose to compete in ROKA’s innovative line of wetsuits, swimskins, goggles, and triathlon race apparel. Over the past four years, Gómez Noya has worn ROKA to victory in three ITU World Triathlon Series titles, two IRONMAN 70.3 World Championships, and an Xterra Off-Road World Championship. Now he’ll be wearing ROKA optics as well as ROKA’s technical race and swim apparel as he attempts to win his first Ironman World Championship in Hawaii this year and cement his legacy as one of the greatest triathletes of all time.

"Javier has been with us every step of the way over the last four years, so we're thrilled to continue that partnership as we take on the challenge of creating the most advanced optics the world has ever seen," says ROKA CEO and Co-Founder, Rob Canales. "Having the input of an athlete of Javier's caliber is critical to the innovation and development of our products. That now includes our latest Maverick X wetsuit , our technical race apparel, and our advanced optics. We look forward to expanding our work with him to redefine standards in the performance eyewear market. It's about pushing limits, and nobody does that better than Javier.”

Gómez Noya will train and race in ROKA’s recently released Advanced Performance sunglasses, designed from scratch to be the lightest, highest performing, and most comfortable eyewear in the world, with unmatched field of vision and fit. “ROKA’s technical apparel and goggles have been a secret weapon for most of my world championships, and now I’m thrilled to have that same world-beating standard for my eyewear as I take on this new challenge of becoming Ironman World Champion,” Gómez Noya says. “My relationship with ROKA is about working together to make something better, and I’m confident that I now have the best eyewear team in the world in my corner for this next phase of my career.”

ROKA’s Advanced Performance eyewear is available in five styles and up to ten different lens tint options, giving athletes the ability to completely customize their eyewear to fit their specific needs. The unique design is the culmination of years of R&D by ROKA’s world-class team of designers and engineers. Weighing between 21 – 25 grams, the collection has set a new standard in the performance optics market that has to be felt to be believed.

Visit www.roka.com or email sales@roka.com to learn more about the company’s growing lines of premium performance eyewear, apparel, and equipment. Follow ROKA on social media at Facebook , Twitter , and Instagram .

About ROKA

ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. Our mission is to unlock human potential. To equip, empower, inspire, and ignite. We serve those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be. When we see an opportunity to innovate, to challenge the status quo, to disrupt a complacent or monopolistic market, we go all in.

Since launching in 2016, ROKA eyewear has been worn to victory by multiple world champions across a variety of sports and challenges, from the Dakar Rally in South America to the Winter Olympics in PyeongChang, South Korea. Gómez Noya is one of 40 elite athletes from all walks of sport who will use Advanced Performance eyewear in 2018, helping them test their limits under the most extreme conditions. For more information, visit www.roka.com/contact

Contact:

Editorial contact
ROKA
Diane Thibert
VP Communications & Public Relations
(310) 804-2400 / diane@roka.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ROKASPORTS/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye